Sorrento Therapeutics (FRA:8STN) Net Change in Cash : €-1.35 Mil (TTM As of Jun. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Sorrento Therapeutics Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Sorrento Therapeutics's Net Change in Cash for the three months ended in Jun. 2023 was €29.62 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2023 was €-1.35 Mil.

Sorrento Therapeutics Net Change in Cash Historical Data

The historical data trend for Sorrento Therapeutics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sorrento Therapeutics Net Change in Cash Chart

Sorrento Therapeutics Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Net Change in Cash

Get a 7-Day Free Trial

169.56

-119.30

-19.98

-17.52

-12.30

Sorrento Therapeutics Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Net Change in Cash	Get a 7-Day Free Trial															-39.32	0.34	-44.42	13.10	29.62

Sorrento Therapeutics Net Change in Cash Calculation

Sorrento Therapeutics's Net Change in Cash for the fiscal year that ended in Dec. 2022 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-277.401	+	-26.921	+	294.262	+	-2.241
	=	-12.30

Sorrento Therapeutics's Net Change in Cash for the quarter that ended in Jun. 2023

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -51.373 + -0.129 + 81.974 + -0.849

= 29.62

Net Change in Cash for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-1.35 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sorrento Therapeutics Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Sorrento Therapeutics's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Sorrento Therapeutics (FRA:8STN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sorrento Therapeutics Inc (FRA:8STN) » Definitions » Net Change in Cash

Comparable Companies

IMUX OCUP KZR HRGN CRDF SABS CDTX NGM KRON MNOV OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XKRX:068270 BNTX ALNY

Traded in Other Exchanges

SRNEQ:USA

Address

4955 Directors Place, San Diego, CA, USA, 92121

Website

https://www.sorrentotherapeutics.com

Sorrento Therapeutics Inc is a clinical and commercial-stage biopharmaceutical company developing a portfolio of next-generation treatments for three major therapeutic areas: cancer, infectious disease, and pain. Its multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (G-MAB library), immuno-cellular therapies (DAR-T), antibody-drug conjugates (ADCs), and oncolytic virus (Seprehvec). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVI-AMG, COVIDROPS, COVISHIELD, FUJOVEE (Abivertinib), and OQORY (Covi-MSC), and diagnostic test solutions, including COVITRACK and COVIMARK.

Sorrento Therapeutics (FRA:8STN) Headlines

No Headlines